Cargando…

Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats

Previous studies have confirmed the clinical efficacy of sacubitril/valsartan (Sac/Val) for the treatment of heart failure with reduced ejection fraction (HFrEF). However, the role of Sac/Val in heart failure with preserved ejection fraction (HFpEF) remains unclear. Sac/Val is a combination therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wenchao, Liu, Jianwei, Fu, Yang, Ji, Huifang, Fang, Zheyan, Zhou, Wanming, Fan, Huimin, Zhang, Yingxuan, Liao, Yan, Yang, Ting, Wang, Xiaolin, Yuan, Wanwan, Chen, Xiaoshu, Dong, Yi-fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841406/ https://www.ncbi.nlm.nih.gov/pubmed/33519461 http://dx.doi.org/10.3389/fphar.2020.600953

Ejemplares similares

Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
por: Guo, Yanhong, et al.
Publicado: (2022)

Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF
por: Schauer, Antje, et al.
Publicado: (2021)

Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022)

Focus on HFpEF in heart failure
por: He, Chunhui, et al.
Publicado: (2022)

Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021)

New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
por: Borlaug, Barry A., et al.
Publicado: (2023)

Left-Side Pressure Index for All-Cause Mortality in Older Adults with HFpEF: Diagnostic Potential for HFpEF and Possible View for HFrEF
por: Hoshida, Shiro
Publicado: (2023)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trial
por: Backhaus, Sören J., et al.
Publicado: (2022)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
por: Martínez-Sellés, Manuel, et al.
Publicado: (2022)

Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants
por: Hiebert, John B., et al.
Publicado: (2016)

Diet-Induced Obesity HFpEF Murine Models
por: Carbone, Salvatore, et al.
Publicado: (2018)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

A preclinical model for phenogroup 3 HFpEF
por: Yousefi, Keyvan, et al.
Publicado: (2019)

Decoding the Pathophysiology of HFpEF With High-Resolution Phenotyping
por: Houstis, Nicholas E.
Publicado: (2020)

Understanding HFpEF With Obesity: Will Pigs Come to the Rescue?
por: Kass, David A.
Publicado: (2021)

Turning Pressure Into Success: Preload Restriction in HFpEF?
por: Atkins, Jessica, et al.
Publicado: (2021)

Renin Feedback Is an Independent Predictor of Outcome in HFpEF
por: Binder, Christina, et al.
Publicado: (2021)

Targeting Collagen Pathways as an HFpEF Therapeutic Strategy
por: Bonanni, Alice, et al.
Publicado: (2023)

The role of imaging in the selection of patients for HFpEF therapy
por: Baron, Tomasz, et al.
Publicado: (2023)

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes
por: Palazzuoli, Alberto, et al.
Publicado: (2021)

Reply: Diet-Induced Obesity HFpEF Murine Models
por: Valero-Muñoz, Maria, et al.
Publicado: (2018)

Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns
por: Sharp, Thomas E., et al.
Publicado: (2019)

Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities
por: Cuijpers, Ilona, et al.
Publicado: (2020)

Cat-apulting Toward a Molecular Understanding of HFpEF
por: Robinson, Emma L., et al.
Publicado: (2021)

Hemodynamic force analysis is not ready for clinical trials on HFpEF
por: Arvidsson, Per M., et al.
Publicado: (2022)

Leukocyte count and the risk of adverse outcomes in patients with HFpEF
por: Zhu, Zhaowei, et al.
Publicado: (2021)

Tolerating Large Preclinical Models of HFpEF But Without the Intolerance?
por: Justo da Silva, Gustavo Jose, et al.
Publicado: (2021)

Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF
por: Barilli, Maria, et al.
Publicado: (2022)

New antidiabetic therapy and HFpEF: light at the end of tunnel?
por: Tadic, Marijana, et al.
Publicado: (2021)

Electrophysiological findings in HFpEF patients presenting for AF ablation
por: Lee, J, et al.
Publicado: (2023)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
por: Al-Jarallah, Mohammed, et al.
Publicado: (2020)

OR19-2 Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) with Low and High Dose of Triiodothyronine: an Animal Model of Metabolic Syndrome with HFpEF
por: Almeida-Coelho, João, et al.
Publicado: (2022)

A horse of a different colour: distinct mechanisms of HFpEF and HFrEF
por: Louch, William E.
Publicado: (2020)

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
por: Singh, Ajmer, et al.
Publicado: (2018)

Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients
por: Nguyen, Quyen L., et al.
Publicado: (2019)

Biomarker profiling for risk of future heart failure (HFpEF) development
por: Watson, Chris J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_igooviglfr2avvenjjt4hqjpbo